VANGUARD GROUP INC 13D and 13G filings for NGM Biopharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2024-02-13 5:09 pm Sale |
2023-12-29 | 13G | NGM Biopharmaceuticals, Inc. NGM |
VANGUARD GROUP INC | 2,770,574 3.350% |
-1,718,575![]() (-38.28%) |
Filing |
2023-02-09 11:27 am Purchase |
2022-12-30 | 13G | NGM Biopharmaceuticals, Inc. NGM |
VANGUARD GROUP INC | 4,489,149 5.490% |
4,489,149![]() (New Position) |
Filing |